Stem Cell Clinic

Entera Bio Appoints Spiros Jamas as Chief Executive Officer

By Global News Feed

BOSTON and JERUSALEM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Spiros Jamas, Sc.D. to the role of Chief Executive Officer and a member of the Board of Directors effective January 4, 2021. Dr. Jamas will succeed Dr. Roger Garceau, who has been serving as interim CEO since August 2020. Dr. Garceau will continue to serve as a Director of Entera Bio.

Read the original here:
Entera Bio Appoints Spiros Jamas as Chief Executive Officer

Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference

By Global News Feed

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held virtually December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020; meetings may be requested through Piper Sandler.

Read the rest here:
Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

VANCOUVER, British Columbia and SEATTLE, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase a total of 147,477 shares of common stock with a grant date of November 30, 2020 (the “Inducement Grant”) for Eric Bjerkholt, the Company’s chief financial officer.

Go here to read the rest:
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

By Global News Feed

ROCKVILLE, MD and CHICAGO, IL, Nov. 30, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has partnered with EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the United States, if approved.

Continue reading here:
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

Sanofi: Information concerning the total number of voting rights and shares – October 2020

By Global News Feed

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Here is the original post:
Sanofi: Information concerning the total number of voting rights and shares - October 2020

Braingrid Limited Announces Proposed Change of Business to an Investment Company and Proposed Name Change

By Global News Feed

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Braingrid Limited (CSE: BGRD) (“Braingrid” or the “Company”) is pleased to announce that it will be pursuing a change of business to an investment company (the “Proposed COB”) under the rules of the Canadian Securities Exchange (the “CSE”).

See original here:
Braingrid Limited Announces Proposed Change of Business to an Investment Company and Proposed Name Change

Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006

By Global News Feed

SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the China National Medical Products Administration (NMPA) has recently accepted its Investigational New Drug (IND) application for JS006, a humanized monoclonal antibody against a human lymphocyte inhibitory receptor TIGIT.

Go here to see the original:
Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006

Tower One Announces Third Quarter 2020 Results and Provides an Update on the Progress of the Business

By Global News Feed

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- TOWER ONE WIRELESS CORP. (CSE: TO) (OTCQB: TOWTF) (Frankfurt: 1P3N) (“Tower One” or the “Company”) announces that it has filed its financial results for the third quarter of 2020, and the related Management’s Discussion and Analysis, the details of which are available on the System for Electronic Document Analysis and Retrieval at www.sedar.com.

Here is the original post:
Tower One Announces Third Quarter 2020 Results and Provides an Update on the Progress of the Business

→←